GLP-1 Drugs Wegovy Ozempic Semaglutide GLP-1 Agonists Mounjaro GLP-1 Medications Novo Nordisk Zepbound Tirzepatide Clinical Trials GLP-1 Receptor Agonists GLP-1s Eli Lilly GLP-1 Treatments Market Trends Approval and Availability Financial Barriers Cost Reduction and Access Petrelintide Market Competition Regulatory Issues GLP-1 Side Effects Viking Therapeutics Metsera Consumer Access Diabetes Treatments FDA Approvals Regulation Tirzepatide vs. Semaglutide Comparison Clinical Studies Market Availability Semaglutide and Tirzepatide Cost Barriers Effectiveness Studies Prescription Medications GLP Inhibitors Insurance Coverage Obesity Treatments Incretin Drugs Survodutide Amycretin Tirzepatide (Zepbound) Challenges
BMO maintains a Market Perform rating despite early U.S. demand for the new pill.
